Central venous line infections in AIDS

Journal of Infection

Volumn 34, Issue 1, 1997, Pages 35-40

  Moore, D A J ^a   Gazzard, B G ^a   Nelson, M R ^a  

^a Chelsea and Westminster Healthcare   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PSEUDOMONAS; RETINITIS; SEPTICEMIA;

EID: 0031039219     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(97)80007-2     Document Type: Article

References (45)

1. Jacobson MA, de Miranda P, Cederberg DM et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 1987; 31: 1251-1254.
2. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS 1995; 9: 471-475.
3. Sjovall J, Karlsson A, Ogenstad S, Sandstrom E, Saarimaki M. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 1988; 44: 65-73.
4. Laskin OL, Cederberg DM, Mills J et al. Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 1987; 83: 201-207.
5. Holland GN, Sidikaro Y, Krieger AE et al. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 1987; 94: 815-823.
6. Walmsley SL, Chew E, Read SE et al. Treatment of cytomegalovirus retinitis with dihydroxypropoxymethylguanine. J Infect Dis 1988; 157: 569-572.
7. Lehoang P, Girard B, Robinet M et al. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989; 96: 865-874.
8. Polsky B, Gold JMW, Whimbey E et al. Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 38-41.
9. Simberkoff MS, Sadr WE, Schiffman G, Rahal JJ. Streptococcus pneumoniae infections and bacteraemia in patients with acquired immune deficiency syndrome with a report of pneumococcal vaccine failure. Am Rev Respir Dis 1984; 130: 1174-1176.
10. Schwann HT, Janowitz SR. Haemophilus influenzae pneumonia in young adults with AIDS, ARC or at risk of AIDS. Am J Med 1989; 86: 11-14.
11. Celum CI, Chaisson RE, Rutherford GW et al. Incidence of salmonellosis in patients with AIDS. J Infect Dis 1987; 156: 998-1002.
12. Manfredi R, Costigliola P, Ricchi E, Chiodo F. Sepsis-bacteraemia and other infections due to non-opportunistic bacterial pathogens in a consecutive series of 788 patients hospitalised for HIV infection. Clinica Terapeutica 1993; 143: 279-290.
13. Stein M, O'Sullivan P, Wachtel T et al. Causes of death in persons with human immunodeficiency virus infection. Am J Med 1992; 93: 387-390.
14. Roilides E, Marshall D, Venzon D et al. Bacterial infections in human immunodeficiency virus type 1 - infected children: the impact of central venous catheters and antiretroviral agents. Paed Inf Dis J 1991; 10: 813-819.
15. Mukau L, Talamani MA, Sitzmann JV, Burns RC, McGuire ME. Long term central venous access vs other home therapies: complications in patients with acquired immunodeficiency syndrome. J Parenter Enteral Nutr 1992; 16: 455-459.
16. Greene FL, Moore W, Strickland G, McFarland J. Comparison of a totally implantable access device for chemotherapy (Port-a-Cath) and long term percutaneous catheterization (Broviac). South Med J 1988; 81: 580-583.
17. Pegues D, Axelrod P, McClaren C et al. Comparison of infections in Hickman and implanted port catheters in adult solid tumour patients. J Surg Oncol 1992; 49: 156-162.
18. May GS, Davis D. Percutaneous catheters and totally implantable access systems: a review of reported infection rates. J Intravenous Nurs 1988; 11: 97-103.
19. Caldwell JW, Melendez PR, Johnson RH. Experience in seventy six patients comparing subcutaneous infusion ports and implanted right atrial catheters. Clin Res 1990; 38: 113A.
20. Riikonen P, Saarinen UM, Lahteenoja KM, Jalanko H. Management of indwelling central venous catheters in pediatric cancer patients with fever and neutropenia. Scand J Infect Dis 1993; 25: 357-364.
21. Keung YK, Watkins K, Chen SC, Groshen S, Silberman H, Douer D. Comparative study of infectious complications of different types of chronic central venous access devices. Cancer 1994; 73: 2832-2837.
22. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine (Baltimore) 1984; 63: 189-200.
23. Drew WL. Cytomegalovirus infections in patients with AIDS. Clin Infect Dis 1992; 14: 608-615.
24. Sloand E, Kumar P, Klein HG, Merritt S, Sacher R. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infections. Transfusion 1994; 34: 48-53.
25. Abramson JS, Mills EL. Depression of neutrophil function induced by viruses and its role in secondary microbial infections. Rev Inf Dis 1988; 10: 326-341.
26. Fernandez-Martin J, Salmon-Ceron D, Leport C et al. Septicemies sur catheters veineux centraux implantes chez les malades atteints de SIDA. Med Mal Infect 1992; 22: 913-918.
27. Skoutelis AT, Murphy RL, MacDonell KB et al. Indwelling central venous catheter infections in patients with Acquired Immune Deficiency Syndrome. J AIDS 1990; 3: 335-342.
28. Raviglione MC, Battan R, Pablos-Mendez A et al. Infections associated with Hickman catheters in patients with Acquired Immunodeficiency Syndrome. Am J Med 1989; 86: 780-786.
29. Northfelt D, Polsky B. Bacteraemia in patients with HIV infection. In: Volberding P, Jacobson MA, eds. AIDS Clinical Review 1991. New York: Marcel Dekker, 1991.
30. Dick L, Mauro MA, Jaques PF, Buckingham P. Radiologic insertion of Hickman catheters in HIV - positive patients: infectious complications. J Vasc Interv Radiol 1991; 2: 327-329.
31. Hamilton JR, Overall JC. Synergistic infection with a murine cytomegalovirus and Pseudomonas aeruginosa in mice. J Infect Dis 1978; 137: 775-781.
32. Nelson MR, Shanson DC, Barter GJ, Hawkins DA, Gazzard BG. Pseudomonas septicaemia associated with HIV. AIDS 1991; 5: 761-763.
33. Meinert CL, Jabs DA, Davis MD et al. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus. New Engl J Med 1992; 326: 213-220.
34. Ranson MR, Oppenheim BA, Jackson A, Kamthan AG, Scarffe JH. Double blind placebo controlled trial of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J Hosp Infect 1990; 15: 95-102.
35. Lim SH, Smith MP, Salooja N, Machin SJ, Goldstone AH. A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter related sepsis in patients receiving intensive chemotherapy for haematological malignancies. J Antimicrob Chemother 1991; 28: 109-116.
36. Bock SN, Lee RE, Fisher B et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple lumen catheter sepsis in patients treated with immunotherapy. J Clin Oncol 1990; 8: 161-169.
37. Lim SH, Smith MP, Machin SJ, Goldstone AH. A prospective randomized study of prophylactic teicoplanin to prevent early Hickman catheter related sepsis in patients receiving intensive chemotherapy for haematological malignancies. Eur J Haematol 1993 Supplementum. 54: 10-13.
38. Miles SA, Mitsuyasu RT, Moreno J et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases haematologic toxicity from zidovudine. Blood 1991; 77: 2109-2117.
39. Gadish M, Kletter Y, Flidel O, Nagler A, Slavin S, Fabian I. Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leuk Res 1991; 15: 1175-1182.
40. Garavelli P, Berti P. Efficacy of recombinant granulocyte colony-stimulating factor in the long term treatment of AIDS-related neutropenia. (letter). AIDS 1993; 7: 589-600.
41. Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients, (letter). AIDS 1992; 6: 515-516.
42. Van Der Pijl H, Frissen PHJ. Experience with a totally implantable venous access device (Port-a-Cath) in patients with AIDS. AIDS 1992; 6: 707-713.
43. Rosenthal JH, Langley C, Lederman M. Sepsis from implanted catheters in patients with AIDS. Fifth International Conference on AIDS, Montreal, June 1989 (Abstract MBP 89).
44. Kumar PN, Collins MS, Pierce PF. Anti-lipopolysaccharide antibody levels in patients with AIDS at the onset of Pseudomonas aeruginosa bacteraemia. J AIDS 1994; 7: 587-591.
45. Bodey GP, Jadeja L, Elting L et al. Pseudomonas bacteraemia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 79: 8-14.